The effects of vitamin E and selenium on cisplatininduced nephrotoxicity in cancer patients treated with cisplatin-based chemotherapy: A randomized, placebo-controlled study

Journal of Research in Medical Sciences

Volumn 17, Issue 1 SPL.1, 2012, Pages

  Hemati, Simin ^a   Jolfaie, Nafiseh Arbab ^a   Gookizadeh, Abbas ^a   Rafienia, Mohammad ^b   Ghavamnasiri, Mohammad Reza ^c  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chemotherapy; Cisplatin; Glomerular filtration rate; Myelosuppression; Nephrotoxicity; Selenium; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; BLEOMYCIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; HEMOGLOBIN; MAGNESIUM SULFATE; PACLITAXEL; PLACEBO; POTASSIUM CHLORIDE; SODIUM SELENITE;

ADULT; AGED; ARTICLE; BLADDER CANCER; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; GLOMERULUS FILTRATION RATE; HEAD AND NECK CANCER; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOCYTE COUNT; LUNG CANCER; MALE; MALIGNANT MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; TESTIS CANCER; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL; UTERINE CERVIX CANCER;

EID: 84874713234     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. DeVita VT, Lawrence TS, Rosenberg SA. Cancer principles & practice of oncology: Annual advances in oncology. New York: Lippincott Williams &; Wilkins; 2011.
2. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci 2007; 334(2): 115-124.
3. Weijl NI, Elsendoorn TJ, Lentjes EG, Hopman GD, Wipkink-Bakker A, Zwinderman AH, et al. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer 2004; 40(11): 1713-1723.
4. Tilgner S. The contented kidney. Medical Herbalism 1998; 10(3): 5-13.
5. Luciak M. Antioxidants in the treatment of patients with renal failure.Rocz Akad Med Bialymst 2004; 49: 157-161.
6. Galland L. Drug-supplement interactions in Lyme disease. [Online]. 2006; Available from URL: http://www.mdheal.org/healthprofessionals/pdf/lymedrugintera ctions.pdf
7. Messina G, Lissoni P, Marchiori P, Bartolacelli E, Brivio F, Magotti L. Enhancement of the efficacy of cancer chemotherapy by the pineal hormone melatonin and its relation with the psychospiritual status of cancer patients. J Res Med Sci 2010; 15(4): 225-228.
8. Lamson DW, Brignall MS. Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Altern Med Rev 1999; 4(5): 304-329.
9. Ajith TA, Abhishek G, Roshny D, Sudheesh NP. Cosupplementation of single and multi doses of vitamins C and E ameliorates cisplatin-induced acute renal failure in mice. Exp Toxicol Pathol 2009; 61(6): 565-571.
10. Atasayar S, Gurer-Orhan H, Orhan H, Gurel B, Girgin G, Ozgunes H. Preventive effect of aminoguanidine compared to vitamin E and C on cisplatin -induced nephrotoxicity in rats. Exp Toxicol Pathol 2009; 61(1): 23-32.
11. Maliakel DM, Kagiya TV, Nair CK. Prevention of cisplatininduced nephrotoxicity by glucosides of ascorbic acid and alpha- tocopherol. Exp Toxicol Pathol 2008; 60(6): 521-527.
12. Ajith TA, Usha S, Nivitha V. Ascorbic acid and alphatocopherol protect anticancer drug cisplatin induced nephrotoxicity in mice: a comparative study. Clin Chim Acta 2007; 375(1-2): 82-86.
13. Naziroglu M, Karaoglu A, Aksoy AO. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology 2004; 195(2-3): 221-230.
14. Noori S, Mahboob T. Protective role of sodium selenite on cisplatin induced oxidative and renal stress. Journal of Basic and Applied Sciences 2008; 4(1): 5-12.
15. Berry JP, Pauwells C, Tlouzeau S, Lespinats G. Effect of selenium in combination with cis-diamminedichloroplatinum(II) in the treatment of murine fibrosarcoma. Cancer Res 1984; 44(7): 2864-2868.
16. Ohkawa K, Tsukada Y, Dohzono H, Koike K, Terashima Y. The effects of co-administration of selenium and cis-platin (CDDP) on CDDP-induced toxicity and antitumour activity. Br J Cancer 1988; 58(1): 38-41.
17. Fauci AS. Harrison's principles of internal medicine. 17th ed. New York: McGraw-Hill Medical; 2008.
18. Palevsky PM. Definition of acute kidney injury (acute renal failure). [Online]. 2012 [cited 11 Apr 2012]; Available from URL: http://www.uptodate.com/contents/definition-of-acutekidney-injury-acute-renalfaiure?source=search_result&search=definition+of+acute+kidney+injury&selectedTitle=1~150. 2012.
19. Chu E. Physicians' cancer chemotherapy drug manual 2010. 10th ed. Canada: Jones &; Bartlett Publishers; 2011.
20. Hu YJ, Chen Y, Zhang YQ, Zhou MZ, Song XM, Zhang BZ, et al. The protective role of selenium on the toxicity of cisplatincontained chemotherapy regimen in cancer patients. Biol Trace Elem Res 1997; 56(3): 331-41.
21. Castiglione F, Dalla MA, Porcile G. Protection of normal tissues from radiation and cytotoxic therapy: the development of amifostine. Tumori 1999; 85(2): 85-91.
22. Capizzi RL. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects. Semin Oncol 1999; 26(2 Suppl 7): 72-81.
23. Nisar S, Feinfeld DA. N-acetylcysteine as salvage therapy in cisplatin nephrotoxicity. Ren Fail 2002; 24(4): 529-533.
24. Dickey DT, Wu YJ, Muldoon LL, Neuwelt EA. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther 2005; 314(3): 1052-1058.
25. Ciarimboli G, Ludwig T, Lang D, Pavenstadt H, Koepsell H, Piechota HJ, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 2005; 167(6): 1477-1484.
26. Ludwig T, Riethmuller C, Gekle M, Schwerdt G, Oberleithner H. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int 2004; 66(1): 196-202.
27. Kroning R, Lichtenstein AK, Nagami GT. Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines. Cancer Chemother Pharmacol 2000; 45(1): 43-49.
28. Esposito M, Viale M, Vannozzi MO, Zicca A, Cadoni A, Merlo F, et al. Effect of the antiarrhythmic drug procainamide on the toxicity and antitumor activity of cisdiamminedichloroplatinum(II). Toxicol Appl Pharmacol 1996; 140(2): 370-377.
29. Viale M, Vannozzi MO, Pastrone I, Mariggio MA, Zicca A, Cadoni A, et al. Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role? J Pharmacol Exp Ther 2000; 293(3): 829-836.
30. Lynch ED, Gu R, Pierce C, Kil J. Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear Res 2005; 201(1-2): 81-89.
31. Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, et al. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 2001; 60(6): 2118-2128.
32. Ramesh G, Reeves WB. Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha. Kidney Int 2004; 65(2): 490-9.
33. Li G, Sha SH, Zotova E, Arezzo J, Van de Water T, Schacht J. Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action. Lab Invest 2002; 82(5): 585-596.
34. Eshraghi-Jazi F, Nematbakhsh M, Nasri H, Talebi A, Haghighi M, Pezeshki Z, et al. The protective role of endogenous nitric oxide donor (l -arginine) in cisplatin-induced nephrotoxicity: Gender related differences in rat model. J Res Med Sci 2011; 16(11): 1389-1396.
35. Nagothu KK, Bhatt R, Kaushal GP, Portilla D. Fibrate prevents cisplatin-induced proximal tubule cell death. Kidney Int 2005; 68(6): 2680-2693.